Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
Autor principal: | Akter, Anika |
---|---|
Otros Autores: | Alam, Marzia |
Formato: | Tesis |
Lenguaje: | English |
Publicado: |
Brac University
2022
|
Materias: | |
Acceso en línea: | http://hdl.handle.net/10361/17039 |
Ejemplares similares
-
Biologics and Biosimilars as Treatment Options for Psoriasis
por: Moya, Amena Khatun
Publicado: (2023) -
Importance of biologics in rheumatoid arthritis management
por: Riyadh, S. M.
Publicado: (2022) -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
por: Afroza, Halima
Publicado: (2024) -
Importance of biologically active agents over other therapies in Rheumatoid Arthritis- a review
por: Mehreen, Elnaj
Publicado: (2021) -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
por: Islam, Nahidul
Publicado: (2023)